Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 45 Neuroblastoma 16 Glioma 16 Brain Neoplasms 14 Astrocytoma 10 Neoplasms 8 Rhabdomyosarcoma 7 Sarcoma, Ewing 6 Recurrence 5 Oligodendroglioma 5 Medulloblastoma 5 Sarcoma 4 Osteosarcoma 4 Melanoma 4 Small Cell Lung Carcinoma 3 Neuroendocrine Tumors 3 Neuroectodermal Tumors, Primitive 3 Lymphoma 3 Gliosarcoma 3 Diffuse Intrinsic Pontine Glioma 3 Wilms Tumor 2 Rhabdoid Tumor 2 Pyloric Stenosis, Hypertrophic 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Ganglioneuroblastoma 2 Fallopian Tube Neoplasms 2 Ependymoma 2 Colorectal Neoplasms 2 Central Nervous System Neoplasms 2

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pan-tumor × Temozolomide × Clear all

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co., Ltd.

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡